Next Generation News and Research

RSS

RNAConnect launches the UltraMarathonRT Direct RNA‑Seq Kit to advance nanopore-based native RNA sequencing

RNAConnect, a life science company providing next generation tools to the RNA community, today announced the commercial availability of the UltraMarathonRT® Direct RNA‑Seq (uMRT DRS) Kit, a native‑RNA library preparation solution for Oxford Nanopore Technologies® direct RNA sequencing (SQK-RNA004).

From RNAConnect 17 Dec 2025

Early life gut microbiome crucial for immune system development

Antibiotics are powerful treatments that have saved countless lives over the course of decades. New findings from Scripps Research have identified a way to preserve healthy immune development even when infants need antibiotic treatment.

17 Dec 2025

Novel cryo-EM findings could revolutionize T cell immunotherapy design

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack dangerous cells. Yet a full understanding of how they actually work has eluded researchers.

16 Dec 2025

SARS-CoV-2 evolves after jumping from humans to zoo animals

Research on SARS-CoV-2 in zoo tigers, lions, and hyenas shows rapid viral evolution and adaptation, offering insights into cross-species transmission dynamics.

16 Dec 2025

GDF3 protein sustains harmful inflammation in aging immune cells

As people age, their bodies develop a dysfunctional immune system, which can leave older adults more susceptible to conditions like sepsis.

15 Dec 2025

Metagenomics reveals overlooked viral risks in treated water

Viruses are everywhere in wastewater treatment plants, quietly interacting with bacteria as sewage is cleaned and reused.

15 Dec 2025

Novel diagnostic approach enables detection of antibiotic resistance and pathogenicity in Klebsiella strains

Antibiotic resistance is one of the most pressing—and quietly advancing—challenges facing modern medicine. Among the most dangerous bacterial pathogens driving this crisis is Klebsiella pneumoniae, a microorganism capable of causing severe infections while evading both antibiotics and the human immune system.

15 Dec 2025

Indoor environments expose people to a growing mix of new contaminants

Indoor dust, air and everyday products are exposing people to a growing mix of "new contaminants" inside homes, schools and workplaces, according to a new perspective published in the journal New Contaminants.

13 Dec 2025

SN101 iPSC-derived therapy relieves chronic pain and preserves joints

SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach to chronic pain management and joint tissue preservation.

12 Dec 2025

Van Andel Institute and Cure Parkinson's extend major Parkinson's drug trial initiative

Van Andel Institute and Cure Parkinson's have renewed a funding agreement to support the International Linked Clinical Trials Program, the world's largest drug repurposing clinical trial initiative for Parkinson's disease.

10 Dec 2025

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

10 Dec 2025

Study shines new light on how cancer avoids the mitotic stopwatch pathway

When cell division (mitosis) takes too long, it can be a sign that something is wrong with the cells, for example DNA damage or chromosomal instability.

10 Dec 2025

VALANX Biotech establishes Board of Directors

VALANX Biotech (VALANX), a biotech company developing novel antibody-drug-conjugate (ADC) assets enabled by its GoldenSite™ site-specific protein conjugation technology, today announced the formation of its Board of Directors.

10 Dec 2025

SwRI and Trinity researchers work on next-generation intranasal therapy for PTSD

Southwest Research Institute (SwRI) and Trinity University are developing an intranasal (IN) drug-device combination to treat post-traumatic stress disorder (PTSD).

9 Dec 2025

Small molecule discovery could open the door to new class of treatments for hard-to-treat cancers

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs - a discovery that could open the door to a new class of treatments for leukemia and other hard-to-treat cancers.

9 Dec 2025

Dietary restriction reprograms cancer-fighting immune cells to enhance anti-tumour immunity

Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel Institute scientists and collaborators.

9 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

Older chemical libraries yield new leads for next-generation COVID-19 antivirals

SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid.

8 Dec 2025

PTSD may be linked to accelerated brain aging among World Trade Center responders

Researchers from the Icahn School of Medicine at Mount Sinai have found that post-traumatic stress disorder (PTSD) may be linked to accelerated brain aging among World Trade Center (WTC) responders involved in rescue and recovery operations after the 9/11 terrorist attacks.

8 Dec 2025

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation.

7 Dec 2025

Next Generation News and Research

RNAConnect launches the UltraMarathonRT Direct RNA‑Seq Kit to advance nanopore-based native RNA sequencing

Early life gut microbiome crucial for immune system development

Novel cryo-EM findings could revolutionize T cell immunotherapy design

SARS-CoV-2 evolves after jumping from humans to zoo animals

GDF3 protein sustains harmful inflammation in aging immune cells

Metagenomics reveals overlooked viral risks in treated water

Novel diagnostic approach enables detection of antibiotic resistance and pathogenicity in Klebsiella strains

Indoor environments expose people to a growing mix of new contaminants

SN101 iPSC-derived therapy relieves chronic pain and preserves joints

Van Andel Institute and Cure Parkinson's extend major Parkinson's drug trial initiative

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

Study shines new light on how cancer avoids the mitotic stopwatch pathway

VALANX Biotech establishes Board of Directors

SwRI and Trinity researchers work on next-generation intranasal therapy for PTSD

Small molecule discovery could open the door to new class of treatments for hard-to-treat cancers

Dietary restriction reprograms cancer-fighting immune cells to enhance anti-tumour immunity

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Older chemical libraries yield new leads for next-generation COVID-19 antivirals

PTSD may be linked to accelerated brain aging among World Trade Center responders

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News